Showing 1401-1410 of 5771 results for "".
- Regenxbio Announces Lancet Publication of Phase 1/2a Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMDhttps://modernod.com/news/regenxbio-announces-lancet-publication-of-phase-12a-study-evaluating-abbv-rgx-314-as-a-one-time-gene-therapy-for-wet-amd/2482186/Regenxbio announced the publication of results from the phase 1/2a trial evaluating the safety and tolerability of a single dose of subretinal ABBV-RGX-314 for the treatment of wet age-related macular degeneration (AMD). Two-year data were
- Nanoscope Announces Topline Results from Phase 2b Trial of MCO-010 for Retinitis Pigmentosahttps://modernod.com/news/nanoscope-announces-topline-results-from-randomized-phase-2b-trial-of-mco-010-for-retinitis-pigmentosa/2482183/Nanoscope Therapeutics announced positive topline results after the completion of the 2-year phase 2b RESTORE randomized, controlled clinical trial of its lead program, MCO-010, a mutation-agnostic gene therapy for patients with permanent and severe vision loss from advanced retini
- GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with Lumevoq Gene Therapy at NANOS 2024https://modernod.com/news/gensight-biologics-announces-initial-results-from-new-meta-analyses-on-visual-outcomes-with-lumevoq-gene-therapy-at-nanos-2024/2482159/GenSight Biologics announced initial results of new meta-analyses in Leber Hereditary Optic Neuropathy (LHON), which showed those treated with Lumevoq (GS010; lenadogene nolparvovec) gene therapy experienced a rate of visual recovery greater than that of idebenone-treated patients and untreated (
- Telios Pharma Announces Phase 2 Results for TL-925, a Novel Treatment for Dry Eye Diseasehttps://modernod.com/news/telios-pharma-announces-successful-phase-2-results-for-tl-925-a-novel-treatment-for-dry-eye-disease/2482150/Telios Pharma announced topline results from its phase 2 study assessing TL-925, a first-in-class topical Bruton’s tyrosine kinase (BTK) inhibitor for individuals with moderate to severe dry eye disease (DED). This proof-of-concept, multicenter, randomized, double-masked study evaluated the
- Nicox Announces Presentation of Data on NCX 470 at the 2024 American Glaucoma Society Annual Meetinghttps://modernod.com/news/nicox-announces-presentation-of-data-on-ncx-470-at-the-2024-american-glaucoma-society-annual-meeting/2482143/Nicox SA provided details of poster presentations highlighting data on NCX 470 at the 2024 American Glaucoma Society (AGS) annual meeting, one of the key scientific events in vision research, which was held February 29-March 3, 2024, in Huntington Beach, California. Poster tit
- Oculis Provides Updates on Late-Stage Clinical Trials; Announces Leadership Appointmentshttps://modernod.com/news/oculis-provides-updates-on-late-stage-clinical-trials-announces-leadership-appointments/2482135/Oculis provided updates its late-stage clinical trials, and also announced senior appointments to its management and advisory teams. The announcements were made during it R&D Day on Wednesday, February 28. “2024 promises to be another exciting year for Ocu
- CoFi Announces Market-Wide Availability of its Multi-Provider Financing Solution with CareCredithttps://modernod.com/news/cofi-announces-market-wide-availability-of-its-multi-provider-financing-solution-with-carecredit/2482133/CoFi announced that patient payments with the CareCredit credit card can now be processed through CoFi’s multi-party payments platform. This market-wide availability follows a successful beta period involving joint CoFi and CareCredit customers. “We’ve
- Ocular Therapeutix Announces Board of Directors and Leadership Updateshttps://modernod.com/news/ocular-therapeutix-announces-board-of-directors-and-leadership-updates/2482128/Ocular Therapeutix announced Board of Directors and leadership updates with the addition of Pravin U. Dugel, MD as Executive Chairman; and the additions of Jeffrey S. Heier, MD, Peter K. Kaiser, MD, and Sanjay Nayak, MBBS, PhD, to the Ocular management
- jCyte Announces Pre-Phase 3 Type B Meeting with FDA; Outlines Plans to Start Pivotal Trial of jCell for RPhttps://modernod.com/news/jcyte-announces-pre-phase-3-type-b-meeting-with-fda-outlines-plans-to-start-pivotal-trial-of-jcell-for-rp/2482126/jCyte announced the successful outcome of its pre-phase 3 Type B meeting with the FDA held on January 16, 2024. Additionally, the company is gearing up to commence its pivotal US trial for jCell for retinitis pigmentosa (RP) in the second half of 2024. John Sholar, Chief Executive
- Innovent Announces Primary Endpoint Met in the Phase 3 Trial of TED Candidate; Plans to Submit NDA in Chinahttps://modernod.com/news/innovent-announces-primary-endpoint-met-in-the-phase-3-clinical-trial-of-thyroid-eye-disease-candidate-plans-to-submit-nda-in-china/2482121/Innovent Biologics announced that the primary endpoint has been achieved in the phase 3 registrational study (RESTORE-1) of IBI311, a recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody in Chinese subjects with Thyroid Eye Disease (TED). Innovent plans to submit the new